Cargando…
A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects
BACKGROUND AND OBJECTIVE: Trofinetide, a synthetic analog of tripeptide glycine-proline-glutamate, is an investigational agent for the treatment of Rett syndrome, a neurodevelopmental disorder with affected individuals requiring lifelong support. Food can affect the pharmacokinetic profile of a drug...
Autores principales: | Darwish, Mona, Youakim, James M., Harlick, Jim, DeKarske, Daryl, Stankovic, Serge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188616/ https://www.ncbi.nlm.nih.gov/pubmed/35622206 http://dx.doi.org/10.1007/s40261-022-01156-4 |
Ejemplares similares
-
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
por: Neul, Jeffrey L., et al.
Publicado: (2023) -
Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study
por: Darwish, Mona, et al.
Publicado: (2022) -
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression
por: DeKarske, Daryl, et al.
Publicado: (2020) -
Trofinetide—a new chapter in rett syndrome’s treatment
por: Furqan, Muhammad
Publicado: (2023) -
Palatability and Swallowability of Pimavanserin When Mixed with Selected Food Vehicles: An Exploratory Open-Label Crossover Study
por: Forman, Mark, et al.
Publicado: (2021)